CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer

Open Access

Peer-reviewed

Research Article

Bharat Devapatla,

Affiliation Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
⨯
Ankur Sharma,

Affiliation Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
⨯
Sukyung Woo

* E-mail: sukyung-woo@ouhsc.edu

Affiliation Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Ovarian cancer
Is the Subject Area "Ovarian cancer" applicable to this article?

Thanks for your feedback.
Chemokines
Is the Subject Area "Chemokines" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Cytokine therapy
Is the Subject Area "Cytokine therapy" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Angiogenesis
Is the Subject Area "Angiogenesis" applicable to this article?

Thanks for your feedback.